12 completed, 1 withdrawn. 13 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 12, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow asunaprevir: new trials by email Literature Review of asunaprevir trials Research Report on asunaprevir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects LDV/SOF+ASV, SOF+DCV+SMV, SOF+DCV+ASV - Chronic Hepatitis C Infection | Phase 2 | Completed | Humanity and Health Research Centre | 18 | 2015-01-01 | 2016-03-01 |
| Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen .Asunaprevir, Daclatasvir and BMS - 791325 - Hepatitis C Virus Genotype 4 Infection | Phase 2 | Withdrawn | ANRS, Emerging Infectious Diseases | 2014-12-01 | 2016-02-02 | |
| Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV Asunaprevir and Daclatasvir, Asunaprevir and Daclatasvir with BMS-791325 - HIV-HCV | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 30 | 2014-02-01 | 2017-05-16 |
| Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO) Asunaprevir, Daclatasvir, Ribavirin - Hepatitis C Virus Genotype 4 Infection | Phase 2 | Completed | ANRS, Emerging Infectious Diseases | 60 | 2013-11-01 | 2026-04-13 |
| Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a - HCV-HIV Co-Infection | Phase 2 | Completed | ANRS, Emerging Infectious Diseases | 75 | 2012-12-01 | 2014-09-08 |
| Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications BMS-650032, BMS-790052, BMS-791325 - Chronic Hepatitis C | Phase 2 | Completed | Bristol-Myers Squibb | 320 | 2011-11-30 | 2017-04-27 |
| Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials Daclatasvir, Asunaprevir, Pegylated interferon alfa-2a - Hepatitis C Virus Infection | Phase 2 | Completed | Bristol-Myers Squibb | 276 | 2011-09-01 | 2016-05-27 |
| Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV) - Hepatitis C | Phase 2 | Completed | Bristol-Myers Squibb | 165 | 2011-03-01 | 2015-10-09 |
| An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject BMS-790052, BMS-650032 - Hepatitis C Infection | Phase 2 | Completed | Bristol-Myers Squibb | 43 | 2010-04-01 | 2015-10-09 |
| Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin BMS-650032, Placebo, Peginterferon Alfa-2a - Hepatitis C Virus | Phase 2 | Completed | Bristol-Myers Squibb | 285 | 2010-02-01 | 2015-10-09 |
| Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care BMS-790052, BMS-650032, Pegylated-interferon alfa-2a - Chronic Hepatitis C | Phase 2 | Completed | Bristol-Myers Squibb | 215 | 2009-12-01 | 2015-10-09 |
| A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects BMS-650032, Placebo - Chronic Hepatitis C | Phase 2 | Completed | Bristol-Myers Squibb | 15 | 2008-12-01 | 2011-06-27 |
| A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects BMS-650032 or Placebo - Chronic Hepatitis C | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 24 | 2008-01-01 | 2010-09-13 |
Hepatitis C (5) · Hepatitis C, Chronic (4) · Coinfection (1)
Bristol-Myers Squibb (8) · ANRS, Emerging Infectious Diseases (3) · Humanity and Health Research Centre (1) · National Institutes of Health Clinical Center (CC) (1)
France (8) · United States (8) · Puerto Rico (4) · Germany (3) · Italy (3) · Spain (3) · Argentina (2) · Australia (2) · Ireland (2) · Japan (2) · New Zealand (2) · United Kingdom (2) · Austria (1) · Canada (1) · China (1)
Dominique Roulot, MD (1) · George Lau, MD (1) · Henry Masur, M.D. (1) · Lionel Piroth, MD PhD (1)
PMID 26683763, PMID 22256805, PMID 23178977, PMID 23183526, PMID 23504694, PMID 24184132, PMID 25038486, PMID 25977266, PMID 26473667, PMID 27917405, PMID 29271782
2009 (1), 2014 (1)